Skip to main content
TKNO
NASDAQ Life Sciences

Alpha Teknova Reports 13% Q1 Revenue Growth, Improved Profitability, and Reaffirms 2026 Guidance

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
7
Price
$3.71
Mkt Cap
$195.141M
52W Low
$1.91
52W High
$7.48
Market data snapshot near publication time

summarizeSummary

Alpha Teknova, Inc. announced strong first quarter 2026 financial results, including a 13% increase in revenue and significant improvements in gross margin, Adjusted EBITDA, and Free Cash Outflow, while reaffirming its full-year guidance.


check_boxKey Events

  • Strong Q1 2026 Revenue Growth

    Total revenue for the first quarter 2026 increased by 13% to $11.1 million, compared to $9.8 million in the prior year period.

  • Improved Profitability Metrics

    Gross profit rose to $3.8 million (34.2% margin) from $3.0 million (30.7% margin) in Q1 2025. Adjusted EBITDA improved to negative $2.0 million from negative $2.5 million year-over-year.

  • Reduced Cash Outflow

    Free Cash Outflow decreased to $3.6 million for the quarter, an improvement from $4.3 million in Q1 2025.

  • 2026 Guidance Reaffirmed

    The company reiterated its fiscal year 2026 revenue guidance of $42 million to $44 million and anticipates Free Cash Outflow of less than $10 million.


auto_awesomeAnalysis

Alpha Teknova's first quarter 2026 financial results show continued operational improvements, building on the positive trends from fiscal year 2025. The 13% revenue growth, coupled with better gross margins and reduced cash burn, indicates progress towards sustainable financial health. Reaffirming the full-year revenue and Free Cash Outflow guidance provides investors with confidence in management's outlook despite ongoing net losses. The routine update to the Code of Ethics is administrative and does not impact the company's financial or operational standing. Investors should monitor the company's ability to maintain this growth trajectory and further reduce its net loss and cash outflow in subsequent quarters.

At the time of this filing, TKNO was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $195.1M. The 52-week trading range was $1.91 to $7.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed TKNO - Latest Insights

TKNO
May 07, 2026, 4:32 PM EDT
Source: Wiseek News
Importance Score:
7
TKNO
May 06, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
TKNO
Apr 21, 2026, 5:22 PM EDT
Filing Type: DEF 14A
Importance Score:
8
TKNO
Mar 02, 2026, 5:15 PM EST
Source: Wiseek News
Importance Score:
7
TKNO
Mar 02, 2026, 5:10 PM EST
Filing Type: 10-K
Importance Score:
8
TKNO
Feb 26, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7